Obesity, a social problem worldwide, is characterized by an increase in body weight that results in excessive fat accumulation. Obesity is a major cause of morbidity and mortality and leads to several diseases, including metabolic syndrome, diabetes mellitus, cardiovascular, fatty liver diseases, and cancer. Growing evidence allows us to understand the critical role of adipose tissue in controlling the physic-pathological mechanisms of obesity and related comorbidities. Recently, adipose tissue, especially in the visceral compartment, has been considered not only as a simple energy depository tissue, but also as an active endocrine organ releasing a variety of biologically active molecules known as adipocytokines or adipokines. Based on the complex interplay between adipokines, obesity is also characterized by chronic low grade inflammation with permanently increased oxidative stress (OS). Over-expression of oxidative stress damages cellular structures together with under-production of anti-oxidant mechanisms, leading to the development of obesity-related complications. The aim of this review is to summarize what is known in the relationship between OS in obesity and obesity-related diseases.
One half of a group of 129 men and women (74 men and 55 women), in a cross-over design at, within a self-selected diet, one egg and at least 5 oz of beef daily for 3 months while the other half at one egg and at least 5 oz of poultry and fish daily. Then they reversed their diets for 3 months. Blood samples were drawn by venipuncture before the study started and at the end of the 3 and 6 months, for analyses of serum total cholesterol, triglycerides, and high density lipoprotein cholesterol. No statistically significant changes were found in serum lipids in men. In women serum triglycerides but not other serum lipids were significantly higher when poultry and fish had been ingested.
Early identification of an underlying inborn error of metabolism in newborns with otherwise unexplained seizures may address appropriate disease-specific treatment and provide important tools about the choice of the antiepileptic drugs.Neonatal seizures usually present as prolonged or recurrent, often configuring epileptic status. Striking features of an underlying metabolic disorder include abnormal neurological examination, lethargy and/ or symptoms of acute decompensation.Ex adiuvantibus, trial with intravenous pyridoxine administration could be attempted in refractory unexplained neonatal seizures. Peculiar EEG patterns such as Suppression Burst may address diagnosis and laboratory work-up being most frequently associated to specific metabolic disorders.
In spite of more than one century of clinical and scientific interest on status epilepticus, further definitions of semiological and etiopathogenetical aspects of this challenging condition are still required. Very recent papers proposed a new mode of classification with the aim to define the operational dimensions of status epilepticus and, of course, an appropriate treatment approach based on clinical and etiopathogenetical criteria. Nevertheless, it remains one of the most common neurological emergencies worldwide, and, its pharmacotherapy still represents an "evidence-free zone" because of lack of controlled trials supporting clinical management. Herein, we reviewed the physiopathology of status epilepticus, from the first descriptions to the more recent data on specific immuno-inflammatory patterns and microglial activation. Moreover, the mostly reported criteria of classification and their pharmacological implications were summarized. Treatment stepwise approaches were also sistematically reviewed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.